|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Press Release
Benitec Forms Hepatology Clinical Advisory Board
Published: Oct 19, 2015 7:30 a.m. ET
SYDNEY, Oct. 19, 2015 /PRNewswire/ -- Benitec Biopharma Limited BNTC, +2.42% (asx:BLT), a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today announced the formation of its Hepatology Clinical Advisory Board. The newly appointed Clinical Advisory Board will serve as a strategic resource to Benitec as it continues to develop therapies for the treatment of hepatitis B and C.
Benitec CEO and Managing Director Dr French said, "We are proud to have assembled such a Board of world experts in hepatology. The insight and guidance provided by our Clinical Advisors is a major asset in promoting the successful development of our RNAi-based therapeutics for the treatment of hepatitis B and C."
The inaugural members of the Hepatology Advisory Board include:
Geoffrey McCaughan, PhD, MD, MBBS, FRACP, AW Morrow Professor of Medicine at the Royal Prince Alfred Hospital and the University of Sydney, and Head of the Liver Injury & Cancer Program at the Centenary Institute, Sydney, Australia
Harry Janssen, PhD, MD, Professor of Medicine, Francis Family Chair in Liver Research and Head of Liver Clinic at Toronto Western and Toronto General Hospital, University Health Network, Toronto, Canada
Keyur Patel, MD, Associate Professor of Medicine, Toronto Western Liver Clinic, University Health Network, Toronto, Canada
About Benitec Biopharma Limited: Benitec Biopharma Limited BNTC, +2.42% (asx:BLT) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's disease, chronic neuropathic pain and retinitis pigmentosa. For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.
Contacts:
Company
Investor relations
United States
Carl Stubbings
Chief Business Officer
Tel: +61 (2) 9555 6986
Email: [email protected]
Kyahn Williamson
Buchan Consulting
Tel: +61 (3) 9866 4722
Email: [email protected]
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
Tel: +1 212 375 2664
Email: [email protected]
Andrew Mielach (Media)
Tel: +1 212 375 2694
Email: [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-r ... oard-300161711.html
SOURCE Benitec Biopharma
Copyright (C) 2015 PR Newswire. All rights reserved
|
|
发表于 2015-10-20 09:36